Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExpressGraft-C9T1 in Diabetic Foot Ulcers
NCT04134143Phase 1Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ExpressGraft-C9T1 in diabetic foot ulcer (DFU) (3 cohorts), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Number of participants with adverse events at Week 12 and Number of participants with adverse events through study completion at 12 months. Started Nov 2019; status: terminated.
02
Drugs
ExpressGraft-C9T1
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT04134143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134143.